An 83-year-old patient with RET fusion-positive non-small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37051304/
An 83-year-old woman with RET fusion-positive advanced lung adenocarcinoma was administered selpercatinib 320 mg/day. Despite the shrinking of the tumour, fever, fatigue, and anorexia developed on day 17. Selpercatinib administration...
Conclusions/Relevance: Selpercatinib is a reasonable treatment option for RET fusion-positive advanced non-small cell lung cancer even in older patients. However, old age may be a risk factor for adverse events including hepatic disorders. For safe treatment in such patients, careful follow-up is required.
Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36985590/
Selpercatinib (SLP; brand name Retevmo ® ) is a selective and potent RE arranged during transfection (RET) inhibitor. On 21 September 2022, the FDA granted regular approval to SLP (Retevmo,...
Conclusions/Relevance: The developed LC-MS/MS method could be applied for therapeutic pharmacokinetic studies or drug monitoring (TDM) for SLP after readjusting the extraction steps using the same chromatographic parameters.
Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36977550/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The cobas EGFR Mutation Test, ddPCR, and NGS appear to be feasible methods for analyzing CSF ctDNA in patients with NSCLC and LM. In addition, NGS may provide comprehensive information regarding the mechanisms underlying osimertinib resistance.
Personalized Systemic Therapies in Hereditary Cancer Syndromes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36980956/
Hereditary cancer syndromes are inherited disorders caused by germline pathogenic variants (PVs) that lead to an increased risk of developing certain types of cancer, frequently at an earlier age than...
Conclusions: In the last decade, germline gene alterations at the basis of several hereditary cancer syndromes have provided optimal targets for the development of personalized cancer treatments. Our review focused on inherited biomarkers; nevertheless, these same molecular alterations may be predictors of treatment response, regardless of...
Molecular genetics of diffuse sclerosing papillary thyroid cancer
AbstractContext. Diffuse sclerosing papillary thyroid cancer (DSPTC) is rare, with limited data on its molecular genetics. We studied the molecular genetics of
Conclusions: In DSPTC, fusion genes are common, BRAFV600E is rare, and other usual point mutations are absent. Pathogenic and likely pathogenic variants in POLE, NF1, CDKN2A, BRCA2, TP53, SETD2, ATM, FLT3 and ROS1 occur in about two-thirds of DTPTC.